Home
About
Disclaimer
Privacy

JCS/T2D - We are advocates. We learn. We share. We inform.

Enter Part of Title

Display #

CVS Caremark Faces Lawsuit Over Dropping Zepbound

Articles

Eli Lilly and Novo Nordisk Invest in Increased Manufacturing Capacity for GLP-1 Drugs
Lifestyle Changes and Anti-Obesity Medications: A Complementary Approach
The Economic Impact of Ozempic on Denmark
Regulatory Hurdles for Awiqli: Approval in Canada and EU, Concerns in the US
Tips for Using a OneTouch Verio Flex Meter
Promising Phase 2 Results: Eli Lilly's Tirzepatide Shows Potential Beyond Diabetes and Obesity
Epigenetic Clues to Heart Risk in Type 2 Diabetes
Addressing Misconceptions: A Closer Look at Weight Loss Drugs and Their Role in Managing Obesity and Type 2 Diabetes
Understanding Incretin Receptor Signaling Bias and Its Potential in Treating Obesity and Type 2 Diabetes
Types of Diabetes
FDA Clears Dexcom's Stelo, First Over-the-Counter Glucose Biosensor for Type 2 Diabetes Management
Why I Took Medical Courses to Strengthen My Data Skills
Novo Nordisk Announces Positive Results in Phase 3a Trial of IcoSema, a Combination of Semaglutide and Insulin Icodec for Type 2 Diabetes
FDA Approves Lilly's Tirzepatide for Obesity
Novo Nordisk's Stance on Semaglutide for Cosmetic Use
The Power of Exercise and Music in Managing Type 2 Diabetes
Tirzepatide’s Efficacy in Treating Obstructive Sleep Apnea
Viewing Type 2 Diabetes as a Vascular Disease
The Potential of GLP-1 Medications for Type 1 Diabetes
The Dual Roles of GLP-1 and GLP-2 in Metabolic Health

News

October 2025

FDA Approves Novo Nordisk’s Oral Semaglutide for Heart Protection in Type 2 Diabetes
Innovent’s Mazdutide Outperforms Semaglutide in Head-to-Head Trial
Lilly’s Oral GLP-1 Outperforms Farxiga in Type 2 Diabetes Trial
Semaglutide’s Heart Benefits Extend Beyond Weight Loss
Terns Ends Development of Oral Obesity Drug After Phase 2 Results

September 2025

CVS Caremark Faces Lawsuit Over Dropping Zepbound
Dexcom Introduces Smart Basal at EASD 2025
Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
Novo Nordisk Resubmits Once-Weekly Basal Insulin Awiqli® for FDA Review
Novo Nordisk Survey Links Wegovy® to Reduced “Food Noise” and Improved Well-Being
Novonesis and Novo Nordisk Launch Gut Microbiome Collaboration

August 2025

FDA Approves Wegovy for MASH Treatment
FDA Expands Repatha Access to More High-Risk Adults
Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win
Novo Nordisk Expands $499 Cash-Pay Option to Ozempic
Novo Nordisk Strikes $550M RNA Deal with Replicate Bioscience
Signos Press Release Raises Questions About FDA Clearance Claims
Teva Launches First Generic GLP-1 for Obesity
Wegovy Outperforms Mounjaro in Cardiovascular Outcomes

Top Subjects

Type 2 Diabetes
Novo Nordisk
Semaglutide
Obesity Treatment
GLP-1
Wegovy
Eli Lilly
Tirzepatide
Ozempic
Zepbound
Diabetes
Obesity
FDA Approval
Diabetes Management
Cardiovascular Health
Mounjaro
SELECT Trial
Continuous Glucose Monitoring
GLP-1 Therapy
Obesity Management
Metabolic Health
Orforglipron
Disease Modification
Dexcom
CGM
Rybelsus
Clinical Trials
Oral Semaglutide
FDA
Diabetes Treatment

Contact Us

How many eyes does a typical person have?

Search

Search

You are here:
Home
JCS/T2D - A Diabetes Journey

Copyright © 2025 JCS/T2D - A Diabetes Journey. All Rights Reserved.

Joomla! is Free Software released under the GNU General Public License.